<h4>Purpose of review</h4>BRAF alterations are uncommon in chronic lymphocytic leukemia (CLL), yet increasing use of broad genomic profiling has identified them as a recurrent component of MAPK-pathway dysregulation. This evidence concerns the gene BRAF and B-cell chronic lymphocytic leukemia.